Guidelines for treating risk factors should include tools for shared decision making

Fully informed decisions cannot be made unless guidelines consider the effect of treatment on healthy life expectancy, say John S Yudkin and colleagues

[1]  Aesha Drozdowski,et al.  Standards of medical care in diabetes. , 2004, Diabetes care.

[2]  D. Matthews,et al.  Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2015, Diabetologia.

[3]  R. Hayward,et al.  Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes , 1997, Annals of Internal Medicine.

[4]  V. Montori,et al.  Shared decision making in endocrinology: present and future directions. , 2016, The lancet. Diabetes & endocrinology.

[5]  J. Yudkin,et al.  Intensified glucose lowering in type 2 diabetes: time for a reappraisal , 2010, Diabetologia.

[6]  R. Hayward.  Excessive testing of adults with type 2 diabetes , 2015, BMJ : British Medical Journal.

[7]  V. Montori,et al.  The idolatry of the surrogate , 2011, BMJ : British Medical Journal.

[8]  Philip M Clarke,et al.  Development of life-expectancy tables for people with type 2 diabetes. , 2009, European heart journal.

[9]  J. Kellett,et al.  European physicians overestimate life expectancy and the likely impact of interventions in individuals with Type 2 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[10]  C. Elley,et al.  Doctors’ perceptions of the prognostic benefit of statins in patients who have had myocardial infarction , 2009, Internal medicine journal.

[11]  Elizabeth Murray,et al.  Patient reactions to a web-based cardiovascular risk calculator in type 2 diabetes: a qualitative study in primary care , 2015, The British journal of general practice : the journal of the Royal College of General Practitioners.

[12]  C. Mazzucchelli,et al.  Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149 , 2015, Diabetes Care.

[13]  Stephen A. Martin,et al.  Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149 , 2015, Diabetes Care.

[14]  T. Hoffmann,et al.  Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. , 2015, JAMA internal medicine.

[15]  K. Chalkidou.  About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[16]  C. Manisty,et al.  Patient-Accessible Tool for Shared Decision Making in Cardiovascular Primary Prevention: Balancing Longevity Benefits Against Medication Disutility , 2014, Circulation.

[17]  M. Tinetti,et al.  Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. , 2011, Archives of internal medicine.

[18]  R. R. Holman,et al.  UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 , 2013, Diabetologia.

[19]  R. Hayward,et al.  Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. , 2014, JAMA internal medicine.